Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine

Applications to radionuclide therapy employing auger electron-emitting isotopes

Li-Jeen Mah, Christian Orlowski, Katherine Ververis, Assam El-Osta, Tom C. Karagiannis

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

There is an intense interest in the development of radiopharmaceuticals for cancer therapy. In particular, radiopharmaceuticals which involve targeting radionuclides specifically to cancer cells with the use of monoclonal antibodies (radioimmunotherapy) or peptides (targeted radiotherapy) are being widely investigated. For example, the ultra-short range Auger electron-emitting isotopes, which are discussed in this review, are being considered in the context of DNA-targeted radiotherapy. The efficient quantitative evaluation of the levels of damage caused by such potential radiopharmaceuticals is required for assessment of therapeutic efficacy and determination of relevant doses for successful treatment. The DNA double-strand break surrogate marker, γH2AX, has emerged as a useful biomonitor of damage and thus effectiveness of treatment, offering a highly specific and sensitive means of assessment. This review will cover the potential applications of γH2AX in nuclear medicine, in particular radionuclide therapy.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalCurrent Radiopharmaceuticals
Volume4
Issue number1
DOIs
Publication statusPublished - Jun 2011

Keywords

  • γh2ax
  • Auger emitters
  • Double-strand breaks
  • Radionuclides
  • Targeted radiotherapy

Cite this

@article{157aad02bd87498dacf6e391e81b3238,
title = "Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: Applications to radionuclide therapy employing auger electron-emitting isotopes",
abstract = "There is an intense interest in the development of radiopharmaceuticals for cancer therapy. In particular, radiopharmaceuticals which involve targeting radionuclides specifically to cancer cells with the use of monoclonal antibodies (radioimmunotherapy) or peptides (targeted radiotherapy) are being widely investigated. For example, the ultra-short range Auger electron-emitting isotopes, which are discussed in this review, are being considered in the context of DNA-targeted radiotherapy. The efficient quantitative evaluation of the levels of damage caused by such potential radiopharmaceuticals is required for assessment of therapeutic efficacy and determination of relevant doses for successful treatment. The DNA double-strand break surrogate marker, γH2AX, has emerged as a useful biomonitor of damage and thus effectiveness of treatment, offering a highly specific and sensitive means of assessment. This review will cover the potential applications of γH2AX in nuclear medicine, in particular radionuclide therapy.",
keywords = "γh2ax, Auger emitters, Double-strand breaks, Radionuclides, Targeted radiotherapy",
author = "Li-Jeen Mah and Christian Orlowski and Katherine Ververis and Assam El-Osta and Karagiannis, {Tom C.}",
year = "2011",
month = "6",
doi = "10.2174/1874471011104010059",
language = "English",
volume = "4",
pages = "59--67",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers",
number = "1",

}

TY - JOUR

T1 - Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine

T2 - Applications to radionuclide therapy employing auger electron-emitting isotopes

AU - Mah, Li-Jeen

AU - Orlowski, Christian

AU - Ververis, Katherine

AU - El-Osta, Assam

AU - Karagiannis, Tom C.

PY - 2011/6

Y1 - 2011/6

N2 - There is an intense interest in the development of radiopharmaceuticals for cancer therapy. In particular, radiopharmaceuticals which involve targeting radionuclides specifically to cancer cells with the use of monoclonal antibodies (radioimmunotherapy) or peptides (targeted radiotherapy) are being widely investigated. For example, the ultra-short range Auger electron-emitting isotopes, which are discussed in this review, are being considered in the context of DNA-targeted radiotherapy. The efficient quantitative evaluation of the levels of damage caused by such potential radiopharmaceuticals is required for assessment of therapeutic efficacy and determination of relevant doses for successful treatment. The DNA double-strand break surrogate marker, γH2AX, has emerged as a useful biomonitor of damage and thus effectiveness of treatment, offering a highly specific and sensitive means of assessment. This review will cover the potential applications of γH2AX in nuclear medicine, in particular radionuclide therapy.

AB - There is an intense interest in the development of radiopharmaceuticals for cancer therapy. In particular, radiopharmaceuticals which involve targeting radionuclides specifically to cancer cells with the use of monoclonal antibodies (radioimmunotherapy) or peptides (targeted radiotherapy) are being widely investigated. For example, the ultra-short range Auger electron-emitting isotopes, which are discussed in this review, are being considered in the context of DNA-targeted radiotherapy. The efficient quantitative evaluation of the levels of damage caused by such potential radiopharmaceuticals is required for assessment of therapeutic efficacy and determination of relevant doses for successful treatment. The DNA double-strand break surrogate marker, γH2AX, has emerged as a useful biomonitor of damage and thus effectiveness of treatment, offering a highly specific and sensitive means of assessment. This review will cover the potential applications of γH2AX in nuclear medicine, in particular radionuclide therapy.

KW - γh2ax

KW - Auger emitters

KW - Double-strand breaks

KW - Radionuclides

KW - Targeted radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=79955703493&partnerID=8YFLogxK

U2 - 10.2174/1874471011104010059

DO - 10.2174/1874471011104010059

M3 - Review Article

VL - 4

SP - 59

EP - 67

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 1

ER -